| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/24/2004 | US6696458 Having x-ray powder diffraction pattern with lines at degrees 2 theta values 6.7, 12.5, 14.0 and 23.9 for cu k alpha radiation of wavelength 1.5406 angstrom |
| 02/24/2004 | US6696452 Glycogen synthase kinase-3 and aurora-2 a serine/threonine protein kinase inhibitors; antidiabetic and anticancer agents and alzheimer's disease treatments |
| 02/24/2004 | US6696446 Benzoylpyridazines, their preparation and use |
| 02/24/2004 | US6696445 Neuropeptide y receptor antagonists comprising heterocyclic nitrogen compounds and/or prodrugs used for prophylaxis of eating and cardiovascular disorders |
| 02/24/2004 | US6696437 Polymerase inhibitors comprising heterocyclic amides such as 2-pyridin-2-ylbenzimidazole-4-carboxamide, used for prophylaxis of neurodegenerative disorders, damage to hearts or brains, and as anticarcinogenic agents |
| 02/24/2004 | US6696431 Administering compounds such as 20(s)-1-alpha,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin d3, for the prophylaxis of skin disorders such as psoriasis |
| 02/24/2004 | US6696427 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 02/24/2004 | US6696414 Use of growth hormone in low dose |
| 02/24/2004 | US6696084 Spray drying process and compositions of fenofibrate |
| 02/24/2004 | US6696059 Administering to patient a therapeutically effective amount of both an n-alkyl derivative of deoxynojirimycin and a glucocerebrosidase enzyme to alleviate or inhibit glycolipid storage disease; gaucher's disease |
| 02/24/2004 | US6695969 Displacement chromatography and involves using a displacer for displacing the hmg-coa reductase inhibitor |
| 02/24/2004 | CA2293461C Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents |
| 02/24/2004 | CA2219081C Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/21/2004 | CA2437664A1 Anti-aging/menopause symptoms relief using ganoderma lucidum spores |
| 02/19/2004 | WO2004015113A2 Albumin-fused ciliary neurotrophic factor |
| 02/19/2004 | WO2004015103A1 Akt2-BINDING PROTEIN |
| 02/19/2004 | WO2004014932A1 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 02/19/2004 | WO2004014931A1 ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME |
| 02/19/2004 | WO2004014930A1 PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-β-D- ALDOHEXOPYRANOSIDES |
| 02/19/2004 | WO2004014928A2 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 02/19/2004 | WO2004014927A1 Mitochondrially targeted antioxidants |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014910A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014896A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
| 02/19/2004 | WO2004014873A1 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| 02/19/2004 | WO2004014861A1 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014856A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/19/2004 | WO2004014851A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004014842A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014427A1 Medicinal composition for lowering blood lipid level |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014407A1 Remedy |
| 02/19/2004 | WO2004014405A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 02/19/2004 | WO2004014403A1 Microorganisms for inhibiting obesity and diabetes mellitus |
| 02/19/2004 | WO2004014395A1 Female hormone-containing patch |
| 02/19/2004 | WO2004014372A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014359A1 Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004014298A2 Composition and method for lowering cholesterol |
| 02/19/2004 | WO2004014150A1 Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004007430A3 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 02/19/2004 | WO2003104473A3 Galactosyl isomalt, method for production and use thereof |
| 02/19/2004 | WO2003092603A3 Composition and method for reducing post-prandial blood glucose |
| 02/19/2004 | WO2003086306A3 5ht2c receptor modulators |
| 02/19/2004 | WO2003082190A3 Spirocyclic amides as cannabinoid receptor modulators |
| 02/19/2004 | WO2003075850A9 Methods for alzheimer's disease treatment and cognitive enhancement |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003059255A3 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003045411A3 Ginger extract preparation |
| 02/19/2004 | WO2003043615A3 Hypertonia treatment during the acute phase of a cerebrovascular accident |
| 02/19/2004 | WO2003025014A3 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 02/19/2004 | WO2002065985A3 Methods of treating diabetes mellitus |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002042328A3 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 02/19/2004 | WO2002032920A3 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034241 Isolating policosanols from a seed or grain processing stream or a vegetable oil processing stream |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034089 Such as (1-((2,3-dihydro-2-(4-propyl-1H-imidazol-2-yl)-1H-indol-1 -yl)carbonyl)propyl)-carbamate; for inactivation of cholecystokinins |
| 02/19/2004 | US20040034078 Such as 2-(2-butylamino-ethylsulfanylmethyl)-1H-benzimidazole-4-carboxylic acid amide for treatment of cancer, strokes, head trauma, and neurodengenerative diseases; solid phase synthesis |
| 02/19/2004 | US20040034070 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/19/2004 | US20040034066 Rosiglitazone hydrochloride is stable, water solubility, high melting point, bulk flow and good for bulk preparation and handling; salt formation |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034052 Antitumor agents |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034037 Heteroaryl compounds useful as inhibitors of GSK-3 |
| 02/19/2004 | US20040034028 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034015 Administering to a human patient suffering from addictive behavior associated with 5HT2C receptor modulation, a fused tetra or pentaheterocyclic compound containing nitrogen in the rings |
| 02/19/2004 | US20040034014 3,7-dihydro-purine-2,6-dione derivatives useful for treating obesity and type II diabetes |
| 02/19/2004 | US20040034008 N-alkylpiperdino-4-yl-urea-pyrazole derivative for treating obesity, metabolic disorders, eating disorders and diabetes |
| 02/19/2004 | US20040034005 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 02/19/2004 | US20040034004 Bicyclic heterocycles for the treatment of diabetes and other diseases |
| 02/19/2004 | US20040034003 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof |
| 02/19/2004 | US20040034000 Methods of treating and/or suppressing insulin resistance |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033985 Composition for regulating animal growth, method of manufacture and use thereof |
| 02/19/2004 | US20040033983 Dietetic mixtures comprising polyglucomannans, excipients and lipase inhibitors such as orlistat |
| 02/19/2004 | US20040033965 Method for treating obesity |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |